SCHEMBL5157539

SCHEMBL5157539

O=C(NN1CCCCC1)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(Cl)cc2Cl)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 14/20 1.00
CNR2 P34972 10/20 0.66
RPA1 P27694 1/20 0.64
CYP2C9 P11712 2/20 0.64
GPR55 Q9Y2T6 2/20 0.64
ABCC4 O15439 1/20 0.64
MLNR O43193 1/20 0.64
ABCB11 O95342 1/20 0.64
CHRM2 P08172 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
ADRA2B P18089 1/20 0.64
ADRA2C P18825 1/20 0.64
DRD1 P21728 1/20 0.64
TBXA2R P21731 1/20 0.64
SLC6A2 P23975 1/20 0.64
HRH2 P25021 1/20 0.64
HTR2A P28223 1/20 0.64
AGTR1 P30556 1/20 0.64
CCKAR P32238 1/20 0.64
CCKBR P32239 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4613969 0.95 CNR1 (0.90) CNR1CNR2RPA1CYP2C9GPR55
SCHEMBL5154664 0.94 CNR1 (0.88) CNR1CNR2RPA1CYP2C9GPR55
SCHEMBL14155480 0.91 CNR1 (0.83) CNR1CNR2
SCHEMBL14155477 0.90 CNR1 (0.81) CNR1CNR2RPA1
SCHEMBL3087783 0.85 CNR1 (0.73) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL3816611 0.84 CNR1 (0.71) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL3087784 0.83 CNR1 (0.71) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL7351242 0.81 CNR1 (0.68) CNR1RPA1LMNAMAPTMEN1
Hydrochloric Acid SCHEMBL9155041 0.81 CNR1 (0.67) CNR1RPA1LMNAMAPTMEN1
SCHEMBL17203783 0.80 CNR1 (0.67) CNR1CNR2RPA1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
WO-2014174457-A1 PYRAZOLE CARBOXYLIC ACID ANALOGUES AS ANTI-MYCOBACTERIAL DRUG CANDIDATES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-10-30 WO disclosed
WO-2014174457-A1 PYRAZOLE CARBOXYLIC ACID ANALOGUES AS ANTI-MYCOBACTERIAL DRUG CANDIDATES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-10-30 WO disclosed
WO-2007017125-A1 CB1 ANTAGONISTS OR INVERSE ANTAGONISTS AS THERAPEUTICAL AGENTS FOR THE TREATMENT OF INFLAMMATION INVOLVING GENE EXPRESSION LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-15 WO disclosed
EP-1752149-A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-14 EP disclosed
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed